These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32463075)

  • 1. Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.
    Schneider LS
    J Prev Alzheimers Dis; 2020; 7(3):199-200. PubMed ID: 32463075
    [No Abstract]   [Full Text] [Related]  

  • 2. The Future of Anti-Amyloid Trials.
    Aisen PS; Cummings J; Doody R; Kramer L; Salloway S; Selkoe DJ; Sims J; Sperling RA; Vellas B
    J Prev Alzheimers Dis; 2020; 7(3):146-151. PubMed ID: 32463066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.
    Kramer LD
    J Prev Alzheimers Dis; 2020; 7(3):142-143. PubMed ID: 32463064
    [No Abstract]   [Full Text] [Related]  

  • 4. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 5. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 6. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Salloway S; Sperling R; Brashear HR
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24724181
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Laske C
    N Engl J Med; 2014 Apr; 370(15):1459. PubMed ID: 24716688
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    de la Torre JC
    N Engl J Med; 2014 Apr; 370(15):1459-60. PubMed ID: 24716689
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Doody RS; Farlow M; Aisen PS;
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24716687
    [No Abstract]   [Full Text] [Related]  

  • 12. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
    Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B
    J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody drugs for Alzheimer's show glimmers of promise.
    Reardon S
    Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
    [No Abstract]   [Full Text] [Related]  

  • 14. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 15. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 16. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
    Aisen PS; Raman R
    J Prev Alzheimers Dis; 2020; 7(3):195-196. PubMed ID: 32463073
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiamyloid therapy for Alzheimer's disease--are we on the right road?
    Karran E; Hardy J
    N Engl J Med; 2014 Jan; 370(4):377-8. PubMed ID: 24450897
    [No Abstract]   [Full Text] [Related]  

  • 18. [Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].
    Peters O
    Dtsch Med Wochenschr; 2014 Mar; 139(10):468. PubMed ID: 24570189
    [No Abstract]   [Full Text] [Related]  

  • 19. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 20. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
    Cehlar O; Skrabana R; Revajova V; Novak M
    Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.